

GLAND PHARMA LIMITED

August 06, 2024

BSE Limited	National Stock Exchange of India Limited
Corporate Relationship Department	Listing Department
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5th floor
25 th floor, Dalal Street	Plot no. C-1, Block G, Bandra Kurla Complex
Mumbai - 400 001	Bandra (East), Mumbai - 400 051
Scrip Code: 543245	Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Ref: <u>Announcement dated August 02, 2024 titled "Conclusion of US FDA Un-announced</u> <u>Inspection at Pashamylaram Facility, Hyderabad"</u>

Sub: <u>Disclosure under Regulation 30 read with Schedule III Para A Sub Para 20 of the SEBI</u> (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is in continuation to our earlier announcement dated August 02, 2024 and details sought by National Stock Exchange of India Limited (NSE) by email dated August 05, 2024. The information required as per Regulation 30 read with Schedule III Para A Sub Para 20 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given below:

Details of Un-announced US FDA Inspection at Pashamylaram Facility, Hyderabad:

SI.	Particulars	Remarks
No		
1	Name of the authority	United States Food and Drug Administration (US FDA)
2	Nature and details of the action(s) taken, initiated or order(s) passed;	Three (3) 483 Observations
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	Not Applicable



5	Impact on financial, operation or other activities Not Applicable
	of the listed entity, quantifiable in monetary
	terms to the extent possible

Request to take the above information on record.

Yours truly,

.

For Gland Pharma Limited

Sampath Kumar Pallerlamudi Company Secretary & Compliance Officer